Ibnsina Pharma (CAI:ISPH) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


CAI:ISPH Ibnsina Pharma CAI:ISPH
87 GF Score
Price E£12.05
GF Value E£10.51
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ibnsina Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CAI:ISPH vs MCK, COR, CAH: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Distribution subindustry, Ibnsina Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ibnsina Pharma Margin of Safety % (DCF Earnings Based) vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Ibnsina Pharma's Margin of Safety % (DCF Earnings Based) falls into.


CAI:ISPH
87GF Score
Ibnsina Pharma CAI:ISPH
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£12.05 is trading 14.7% above its estimated GF Value™ of E£10.51. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: E£10.51 vs. price of E£12.05 (14.7% above fair value)
  • GF Score™: 87/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
87GF Score

Get the complete analysis for CAI:ISPH

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£12.05
Price
E£10.51
GF Value